Cuban lung cancer vaccine submitted in Serbia; U.K. may recommend AZ's FLUENZ for all children over 5;

> The Cuban lung cancer vaccine, Cimavax EGF, will be submitted for approval in Serbia in the fourth quarter of 2012 and could be available in 2013, under a collaboration between CIMAB (Cuban Center of Molecular Immunology of Havana) and the Serbian Torlak Institute. Article

> Differences in levels of T helper cells could explain why some people live longer with HIV and could be a new target for HIV vaccines. Press release

> The U.K. Joint Committee on Vaccination and Immunisation (JCVI) is considering recommending AstraZeneca's FLUENZ live attenuated flu vaccine to all children over age 5. Article

> Antibodies in breast milk could neutralize HIV; these may lead to a new route to HIV vaccination. Press release | Article

> Desentum, a Finnish VTT spinoff, is developing anti-allergy vaccines. Article

> Eurocine Vaccines is developing an experimental nasal pneumococcal vaccine, and this has protected mice against intranasal challenge, giving the same level of protection as a standard injected vaccine. Press release

> Researchers at the University of Adelaide are looking at new strategies to develop meningitis vaccines. Press release

> Advaxis has completed Phase II enrollment of its cervical cancer immunotherapy. Press release

And Finally… City of Hope has been given a $5 million grant to develop a T cell-based immunotherapy against glioma. Press release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.